STAT senior science writer Sharon Begley and national biotech columnist Adam Feuerstein tell us what CRISPR is (and is not), what other genome-editing methods are already being tested, and which companies are betting on these technologies to one day treat, cure, or prevent disease.

This is the year when CRISPR will move out of the lab and into patients in the first U.S. clinical trials of the genome-editing technology. See what Sharon, Adam, and webinar participants think success might look like.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Asi he funcionado toda mi vida. Lo más doloroso fue conocer que mi exesposo junto a los tres niños son los que Provocan caos en mi vida. Es muy pena muy grande. Gracias

  • I attended the webinar on CRISPR, and found it very interesting. I would love to you have that webinar open to the public as it helped me (a 40 your veteran nurse understand this new technology). I would love to share it with my colleagues so they can also understand CRISPR as it roles out to the broader healthcare industry.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy